Although validated genetic tests are used to identify patients whose tumors are likely to respond to EGFR- or ALK-targeted drugs, ~20% of EGFR- and ALK-positive NSCLC patients will be non-responders [19,20,21]. Here, ALK is linked to non-small cell lung carcinoma.